Cancer Research AACR Conference on Molecular Diagnostics - 2008 AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Browder, T.
Right arrow Articles by Folkman, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Browder, T.
Right arrow Articles by Folkman, J.
[Cancer Research 60, 1878-1886, April 1, 2000]
© 2000 American Association for Cancer Research

Experimental Therapeutics

Antiangiogenic Scheduling of Chemotherapy Improves Efficacy against Experimental Drug-resistant Cancer1

Timothy Browder, Catherine E. Butterfield, Birgit M. Kräling, Bin Shi, Blair Marshall, Michael S. O’Reilly and Judah Folkman2

Laboratory of Surgical Research [T. B., C. E. B., B. M. K., B. S., B. M., M. S. O., J. F.] and Division of Hematology/Oncology [T. B.], Children’s Hospital; Departments of Surgery and Cell Biology, Harvard Medical School [J. F.]; Department of Pediatric Oncology, Dana-Farber Cancer Institute [T. B.]; and the Joint Center for Radiation Therapy [M. S. O.], Boston, Massachusetts 02115

To reveal the antiangiogenic capability of cancer chemotherapy, we developed an alternative antiangiogenic schedule for administration of cyclophosphamide. We show here that this antiangiogenic schedule avoided drug resistance and eradicated Lewis lung carcinoma and L1210 leukemia, an outcome not possible with the conventional schedule. When Lewis lung carcinoma and EMT-6 breast cancer were made drug resistant before therapy, the antiangiogenic schedule suppressed tumor growth 3-fold more effectively than the conventional schedule. When another angiogenesis inhibitor, TNP-470, was added to the antiangiogenic schedule of cyclophosphamide, drug-resistant Lewis lung carcinomas were eradicated. Each dose of the antiangiogenic schedule of cyclophosphamide induced the apoptosis of endothelial cells within tumors, and endothelial cell apoptosis preceded the apoptosis of drug-resistant tumor cells. This antiangiogenic effect was more pronounced in p53-null mice in which the apoptosis of p53-null endothelial cells induced by cyclophosphamide was so vigorous that drug-resistant tumors comprising 4.5% of body weight were eradicated. Thus, by using a dosing schedule of cyclophosphamide that provided more sustained apoptosis of endothelial cells within the vascular bed of a tumor, we show that a chemotherapeutic agent can more effectively control tumor growth in mice, regardless of whether the tumor cells are drug resistant.




This article has been cited by other articles:


Home page
 NEJMHome page
R. S. Kerbel
Tumor Angiogenesis
N. Engl. J. Med., May 8, 2008; 358(19): 2039 - 2049.
[Full Text] [PDF]

Home page
 CarcinogenesisHome page
T. Tsuzuki and Y. Kawakami
Tumor angiogenesis suppression by {alpha}-eleostearic acid, a linolenic acid isomer with a conjugated triene system, via peroxisome proliferator-activated receptor {gamma}
Carcinogenesis, April 1, 2008; 29(4): 797 - 806.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
B. Laquente, C. Lacasa, M. M. Ginesta, O. Casanovas, A. Figueras, M. Galan, I. G. Ribas, J. R. Germa, G. Capella, and F. Vinals
Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model
Mol. Cancer Ther., March 1, 2008; 7(3): 638 - 647.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. A. Garcia, H. Hirte, G. Fleming, D. Yang, D. D. Tsao-Wei, L. Roman, S. Groshen, S. Swenson, F. Markland, D. Gandara, et al.
Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia
J. Clin. Oncol., January 1, 2008; 26(1): 76 - 82.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Ma and D. J. Waxman
Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib
Mol. Cancer Ther., January 1, 2008; 7(1): 79 - 89.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. A. Blansfield, D. Caragacianu, H. R. Alexander III, M. A. Tangrea, S. Y. Morita, D. Lorang, P. Schafer, G. Muller, D. Stirling, R. E. Royal, et al.
Combining Agents that Target the Tumor Microenvironment Improves the Efficacy of Anticancer Therapy
Clin. Cancer Res., January 1, 2008; 14(1): 270 - 280.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
P. A. Bunn Jr. and N. Thatcher
Introduction
Oncologist, January 1, 2008; 13(suppl_1): 1 - 4.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
K. Kurozumi, J. Hardcastle, R. Thakur, M. Yang, G. Christoforidis, G. Fulci, F. H. Hochberg, R. Weissleder, W. Carson, E. A. Chiocca, et al.
Effect of Tumor Microenvironment Modulation on the Efficacy of Oncolytic Virus Therapy
J Natl Cancer Inst, December 5, 2007; 99(23): 1768 - 1781.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
M. Caballero, J. J. Grau, J. L. Blanch, J. Domingo-Domenech, J. M. Auge, W. Jimenez, and M. Bernal-Sprekelsen
Serum Vascular Endothelial Growth Factor as a Predictive Factor in Metronomic (Weekly) Paclitaxel Treatment for Advanced Head and Neck Cancer
Arch Otolaryngol Head Neck Surg, November 1, 2007; 133(11): 1143 - 1148.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Ma and D. J. Waxman
Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment
Mol. Cancer Ther., November 1, 2007; 6(11): 2879 - 2890.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. J. Kim, M. Ravoori, C. N. Landen, A. A. Kamat, L. Y. Han, C. Lu, Y. G. Lin, W. M. Merritt, N. Jennings, W. A. Spannuth, et al.
Antitumor and Antivascular Effects of AVE8062 in Ovarian Carcinoma
Cancer Res., October 1, 2007; 67(19): 9337 - 9345.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
H. Klement, B. St. Croix, C. Milsom, L. May, Q. Guo, J. L. Yu, P. Klement, and J. Rak
Atherosclerosis and Vascular Aging as Modifiers of Tumor Progression, Angiogenesis, and Responsiveness to Therapy
Am. J. Pathol., October 1, 2007; 171(4): 1342 - 1351.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Shaked and R. S. Kerbel
Antiangiogenic Strategies on Defense: On the Possibility of Blocking Rebounds by the Tumor Vasculature after Chemotherapy
Cancer Res., August 1, 2007; 67(15): 7055 - 7058.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. M. Bell-McGuinn, A. L. Garfall, M. Bogyo, D. Hanahan, and J. A. Joyce
Inhibition of Cysteine Cathepsin Protease Activity Enhances Chemotherapy Regimens by Decreasing Tumor Growth and Invasiveness in a Mouse Model of Multistage Cancer
Cancer Res., August 1, 2007; 67(15): 7378 - 7385.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Schaller, I. Fuchs, T. Gonsch, J. Weber, A. Kleine-Tebbe, P. Klare, H.-J. Hindenburg, V. Lakner, A. Hinke, and N. Bangemann
Phase II Study of Capecitabine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 Overexpressing Metastatic Breast Cancer Pretreated With Anthracyclines or Taxanes
J. Clin. Oncol., August 1, 2007; 25(22): 3246 - 3250.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Santini, B. Vincenzi, S. Galluzzo, F. Battistoni, L. Rocci, O. Venditti, G. Schiavon, S. Angeletti, F. Uzzalli, M. Caraglia, et al.
Repeated Intermittent Low-Dose Therapy with Zoledronic Acid Induces an Early, Sustained, and Long-Lasting Decrease of Peripheral Vascular Endothelial Growth Factor Levels in Cancer Patients
Clin. Cancer Res., August 1, 2007; 13(15): 4482 - 4486.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Martin and R. Schilder
Novel Approaches in Advancing the Treatment of Epithelial Ovarian Cancer: The Role of Angiogenesis Inhibition
J. Clin. Oncol., July 10, 2007; 25(20): 2894 - 2901.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
S. Kesari, D. Schiff, L. Doherty, D. C. Gigas, T. T. Batchelor, A. Muzikansky, A. O'Neill, J. Drappatz, A. S. Chen-Plotkin, N. Ramakrishna, et al.
Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults
Neuro-oncol, July 1, 2007; 9(3): 354 - 363.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. V. Dickson, J. B. Hamner, T. L. Sims, C. H. Fraga, C. Y.C. Ng, S. Rajasekeran, N. L. Hagedorn, M. B. McCarville, C. F. Stewart, and A. M. Davidoff
Bevacizumab-Induced Transient Remodeling of the Vasculature in Neuroblastoma Xenografts Results in Improved Delivery and Efficacy of Systemically Administered Chemotherapy
Clin. Cancer Res., July 1, 2007; 13(13): 3942 - 3950.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
Q. Zhou, P. Guo, X. Wang, S. Nuthalapati, and J. M. Gallo
Preclinical Pharmacokinetic and Pharmacodynamic Evaluation of Metronomic and Conventional Temozolomide Dosing Regimens
J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 265 - 275.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. A. Kamat, T. J. Kim, C. N. Landen Jr., C. Lu, L. Y. Han, Y. G. Lin, W. M. Merritt, P. H. Thaker, D. M. Gershenson, F. Z. Bischoff, et al.
Metronomic Chemotherapy Enhances the Efficacy of Antivascular Therapy in Ovarian Cancer
Cancer Res., January 1, 2007; 67(1): 281 - 288.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
B. Dome, M. J.C. Hendrix, S. Paku, J. Tovari, and J. Timar
Alternative Vascularization Mechanisms in Cancer: Pathology and Therapeutic Implications
Am. J. Pathol., January 1, 2007; 170(1): 1 - 15.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Suvannasankha, C. Fausel, B. E. Juliar, C. T. Yiannoutsos, W. B. Fisher, R. H. Ansari, L. L. Wood, G. G. Smith, L. D. Cripe, and R. Abonour
Final Report of Toxicity and Efficacy of a Phase II Study of Oral Cyclophosphamide, Thalidomide, and Prednisone for Patients with Relapsed or Refractory Multiple Myeloma: A Hoosier Oncology Group Trial, HEM01-21
Oncologist, January 1, 2007; 12(1): 99 - 106.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
K. Podar, G. Tonon, M. Sattler, Y.-T. Tai, S. LeGouill, H. Yasui, K. Ishitsuka, S. Kumar, R. Kumar, L. N. Pandite, et al.
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma
PNAS, December 19, 2006; 103(51): 19478 - 19483.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. R. Horsman and D. W. Siemann
Pathophysiologic Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional Therapies
Cancer Res., December 15, 2006; 66(24): 11520 - 11539.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. G. Burdelya, E. A. Komarova, J. E. Hill, T. Browder, N. D. Tararova, L. Mavrakis, P. E. DiCorleto, J. Folkman, and A. V. Gudkov
Inhibition of p53 Response in Tumor Stroma Improves Efficacy of Anticancer Treatment by Increasing Antiangiogenic Effects of Chemotherapy and Radiotherapy in Mice
Cancer Res., October 1, 2006; 66(19): 9356 - 9361.
[Abstract] [Full Text] [PDF]

Home page
 Integr Cancer TherHome page
M. F. McCarty and K. I. Block
Preadministration of High-Dose Salicylates, Suppressors of NF-{kappa}B Activation, May Increase the Chemosensitivity of Many Cancers: An Example of Proapoptotic Signal Modulation Therapy.
Integr Cancer Ther, September 1, 2006; 5(3): 252 - 268.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Buckstein, R. S. Kerbel, Y. Shaked, R. Nayar, C. Foden, R. Turner, C. R. Lee, D. Taylor, L. Zhang, S. Man, et al.
High-Dose Celecoxib and Metronomic "Low-dose" Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non-Hodgkin's Lymphoma
Clin. Cancer Res., September 1, 2006; 12(17): 5190 - 5198.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
R. van Amerongen and A. Berns
TXR1-mediated thrombospondin repression: a novel mechanism of resistance to taxanes?
Genes & Dev., August 1, 2006; 20(15): 1975 - 1981.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Zhang, L. Xiang, R. Hassan, C. H. Paik, J. A. Carrasquillo, B.-s. Jang, N. Le, M. Ho, and I. Pastan
Synergistic Antitumor Activity of Taxol and Immunotoxin SS1P in Tumor-Bearing Mice
Clin. Cancer Res., August 1, 2006; 12(15): 4695 - 4701.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. S.W. Ng, A. Sparreboom, Y. Shaked, C. Lee, S. Man, N. Desai, P. Soon-Shiong, W. D. Figg, and R. S. Kerbel
Influence of Formulation Vehicle on Metronomic Taxane Chemotherapy: Albumin-Bound versus Cremophor EL-Based Paclitaxel.
Clin. Cancer Res., July 15, 2006; 12(14): 4331 - 4338.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Mancuso, M. Colleoni, A. Calleri, L. Orlando, P. Maisonneuve, G. Pruneri, A. Agliano, A. Goldhirsch, Y. Shaked, R. S. Kerbel, et al.
Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy
Blood, July 15, 2006; 108(2): 452 - 459.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
R. Saito, M. T. Krauze, C. O. Noble, D. C. Drummond, D. B. Kirpotin, M. S. Berger, J. W. Park, and K. S. Bankiewicz
Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model
Neuro-oncol, July 1, 2006; 8(3): 205 - 214.
[Abstract] [Full Text] [PDF]

Home page
 Integr Cancer TherHome page
M. F. McCarty and K. I. Block
Toward a core nutraceutical program for cancer management.
Integr Cancer Ther, June 1, 2006; 5(2): 150 - 171.
[Abstract] [PDF]

Home page
 FASEB J.Home page
P. Fasanaro, A. Magenta, G. Zaccagnini, L. Cicchillitti, S. Fucile, F. Eusebi, P. Biglioli, M. C. Capogrossi, and F. Martelli
Cyclin D1 degradation enhances endothelial cell survival upon oxidative stress
FASEB J, June 1, 2006; 20(8): 1242 - 1244.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
R. S. Kerbel
Antiangiogenic therapy: a universal chemosensitization strategy for cancer?
Science, May 26, 2006; 312(5777): 1171 - 1175.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. D. Young, M. Whissell, J. C.S. Noble, P. O. Cano, P. G. Lopez, and C. J. Germond
Phase II Clinical Trial Results Involving Treatment with Low-Dose Daily Oral Cyclophosphamide, Weekly Vinblastine, and Rofecoxib in Patients with Advanced Solid Tumors.
Clin. Cancer Res., May 15, 2006; 12(10): 3092 - 3098.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
A. R. Padhani, C. Hayes, L. Assersohn, T. Powles, A. Makris, J. Suckling, M. O. Leach, and J. E. Husband
Prediction of Clinicopathologic Response of Breast Cancer to Primary Chemotherapy at Contrast-enhanced MR Imaging: Initial Clinical Results
Radiology, May 1, 2006; 239(2): 361 - 374.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Munoz, S. Man, Y. Shaked, C. R. Lee, J. Wong, G. Francia, and R. S. Kerbel
Highly Efficacious Nontoxic Preclinical Treatment for Advanced Metastatic Breast Cancer Using Combination Oral UFT-Cyclophosphamide Metronomic Chemotherapy.
Cancer Res., April 1, 2006; 66(7): 3386 - 3391.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
J. V. Heymach
Antiangiogenic Therapy for Cancer: from the Bench to Bedside and Back
Am. Assoc. Cancer Res. Educ. Book, April 1, 2006; 2006(1): 177 - 180.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Naumova, P. Ubezio, A. Garofalo, P. Borsotti, L. Cassis, E. Riccardi, E. Scanziani, S. A. Eccles, M. R. Bani, and R. Giavazzi
The Vascular Targeting Property of Paclitaxel Is Enhanced by SU6668, a Receptor Tyrosine Kinase Inhibitor, Causing Apoptosis of Endothelial Cells and Inhibition of Angiogenesis.
Clin. Cancer Res., March 15, 2006; 12(6): 1839 - 1849.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. Jounaidi, C.-S. Chen, G. J. Veal, and D. J. Waxman
Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11.
Mol. Cancer Ther., March 1, 2006; 5(3): 541 - 555.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
U. Emmenegger, G. C. Morton, G. Francia, Y. Shaked, M. Franco, A. Weinerman, S. Man, and R. S. Kerbel
Low-Dose Metronomic Daily Cyclophosphamide and Weekly Tirapazamine: A Well-Tolerated Combination Regimen with Enhanced Efficacy That Exploits Tumor Hypoxia
Cancer Res., February 1, 2006; 66(3): 1664 - 1674.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Colleoni, L. Orlando, G. Sanna, A. Rocca, P. Maisonneuve, G. Peruzzotti, R. Ghisini, M. T. Sandri, L. Zorzino, F. Nole, et al.
Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects
Ann. Onc., February 1, 2006; 17(2): 232 - 238.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. M. du Manoir, G. Francia, S. Man, M. Mossoba, J. A. Medin, A. Viloria-Petit, D. J. Hicklin, U. Emmenegger, and R. S. Kerbel
Strategies for Delaying or Treating In vivo Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts
Clin. Cancer Res., February 1, 2006; 12(3): 904 - 916.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. A. Reardon, M. J. Egorin, J. A. Quinn, J. N. Rich Sr, I. Gururangan, J. J. Vredenburgh, A. Desjardins, S. Sathornsumetee, J. M. Provenzale, J. E. Herndon II, et al.
Phase II Study of Imatinib Mesylate Plus Hydroxyurea in Adults With Recurrent Glioblastoma Multiforme
J. Clin. Oncol., December 20, 2005; 23(36): 9359 - 9368.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y. Shaked, U. Emmenegger, S. Man, D. Cervi, F. Bertolini, Y. Ben-David, and R. S. Kerbel
Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity
Blood, November 1, 2005; 106(9): 3058 - 3061.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Hu, J. Hofmann, J. Holash, G. D. Yancopoulos, A. K. Sood, and R. B. Jaffe
Vascular Endothelial Growth Factor Trap Combined with Paclitaxel Strikingly Inhibits Tumor and Ascites, Prolonging Survival in a Human Ovarian Cancer Model
Clin. Cancer Res., October 1, 2005; 11(19): 6966 - 6971.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Yap, D. Veliceasa, U. Emmenegger, R. S. Kerbel, L. M. McKay, J. Henkin, and O. V. Volpert
Metronomic Low-Dose Chemotherapy Boosts CD95-Dependent Antiangiogenic Effect of the Thrombospondin Peptide ABT-510: A Complementation Antiangiogenic Strategy
Clin. Cancer Res., September 15, 2005; 11(18): 6678 - 6685.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
C.-S. Chen, Y. Jounaidi, and D. J. Waxman
ENANTIOSELECTIVE METABOLISM AND CYTOTOXICITY OF R-IFOSFAMIDE AND S-IFOSFAMIDE BY TUMOR CELL-EXPRESSED CYTOCHROMES P450
Drug Metab. Dispos., September 1, 2005; 33(9): 1261 - 1267.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Shaked, U. Emmenegger, G. Francia, L. Chen, C. R. Lee, S. Man, A. Paraghamian, Y. Ben-David, and R. S. Kerbel
Low-dose Metronomic Combined with Intermittent Bolus-dose Cyclophosphamide Is an Effective Long-term Chemotherapy Treatment Strategy
Cancer Res., August 15, 2005; 65(16): 7045 - 7051.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. J. Streck, P. V. Dickson, C. Y.C. Ng, J. Zhou, J. T. Gray, A. C. Nathwani, and A. M. Davidoff
Adeno-Associated Virus Vector-Mediated Systemic Delivery of IFN-{beta} Combined with Low-Dose Cyclophosphamide Affects Tumor Regression in Murine Neuroblastoma Models
Clin. Cancer Res., August 15, 2005; 11(16): 6020 - 6029.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
D. S. Riddick, C. Lee, S. Ramji, E. C. Chinje, R. L. Cowen, K. J. Williams, A. V. Patterson, I. J. Stratford, C. S. Morrow, A. J. Townsend, et al.
CANCER CHEMOTHERAPY AND DRUG METABOLISM
Drug Metab. Dispos., August 1, 2005; 33(8): 1083 - 1096.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Bocci, M. Tuccori, U. Emmenegger, V. Liguori, A. Falcone, R. S. Kerbel, and M. Del Tacca
Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation
Ann. Onc., August 1, 2005; 16(8): 1243 - 1252.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. di Tomaso, D. Capen, A. Haskell, J. Hart, J. J. Logie, R. K. Jain, D. M. McDonald, R. Jones, and L. L. Munn
Mosaic Tumor Vessels: Cellular Basis and Ultrastructure of Focal Regions Lacking Endothelial Cell Markers
Cancer Res., July 1, 2005; 65(13): 5740 - 5749.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Li, L. Tian, J.-m. Hou, Z.-y. Ding, Q.-m. He, P. Feng, Y.-j. Wen, F. Xiao, B. Yao, R. Zhang, et al.
Improved Therapeutic Effectiveness by Combining Recombinant CXC Chemokine Ligand 10 with Cisplatin in Solid Tumors
Clin. Cancer Res., June 1, 2005; 11(11): 4217 - 4224.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. E. Huber, M. Bischof, J. Jenne, S. Heiland, P. Peschke, R. Saffrich, H.-J. Grone, J. Debus, K. E. Lipson, and A. Abdollahi
Trimodal Cancer Treatment: Beneficial Effects of Combined Antiangiogenesis, Radiation, and Chemotherapy
Cancer Res., May 1, 2005; 65(9): 3643 - 3655.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Beaudry, J. Force, G. N. Naumov, A. Wang, C. H. Baker, A. Ryan, S. Soker, B. E. Johnson, J. Folkman, and J. V. Heymach
Differential Effects of Vascular Endothelial Growth Factor Receptor-2 Inhibitor ZD6474 on Circulating Endothelial Progenitors and Mature Circulating Endothelial Cells: Implications for Use as a Surrogate Marker of Antiangiogenic Activity
Clin. Cancer Res., May 1, 2005; 11(9): 3514 - 3522.
[Abstract] [Full Text] [PDF]